Compound: 4-Amino-3-phenylbutanoic acid
SMILES: O=C(O)CC(c1ccccc1)CN
InChIKey: DAFOCGYVTAOKAJ-UHFFFAOYSA-N
Synonyms: 4-Amino-3-phenylbutanoic acid, Phenibut, 1078-21-3, Fenibut, 4-Amino-3-phenylbutyric acid, PhGaba, phenigamma, phenygam, beta-(Aminomethyl)benzenepropanoic acid, beta-Phenyl-gamma-aminobutyric acid, beta-(Aminomethyl)hydrocinnamic acid, T2M58D6LA8, Dl-4-amino-3-phenylbutanoic acid, DTXSID70870838, phenyl-GABA, phenybut, citrocard, noophen, RefChem:517857, DTXCID80818524, 214-079-6, Fenigam, Benzenepropanoic acid, beta-(aminomethyl)-, MFCD00456233, Phenylgamma, Benzenepropanoic acid, b-(aminomethyl)-, Phenylgam, Fenigama, Phenigam, Pgaba, Phenigama, (3R)-4-amino-3-phenylbutanoic acid, (3S)-4-amino-3-phenylbutanoic acid, beta-Phenyl-gamma-aminobutyrate, EINECS 214-079-6, BRN 2804903, UNII-T2M58D6LA8, 4-amino-3-phenyl-butanoic acid, Phenibut; Fenibut, BUTYRIC ACID, 4-AMINO-3-PHENYL-, Benzenepropanoic acid, .beta.-(aminomethyl)-, PHENIBUT [WHO-DD], Oprea1_183000, Oprea1_381119, 4-14-00-01723 (Beilstein Handbook Reference), (+/-)-FENIBUT, SCHEMBL340838, 3-phenyl-4-aminobutanoic acid, CHEMBL315818, EX-A734, CHEBI:136039, GLXC-20028, HMS3886K05, butanoic acid, 4-amino-3-phenyl-, ALBB-022462, MSK11183, BBL000576, EBC-44072, s4892, SBB001567, STK182861, (+/-)-.BETA.-PHENYL-GABA, 3-amino-2-phenylpropanecarboxylic acid, AKOS000555914, AKOS016347357, CCG-266416, DB13455, GS-3145, 3-[3-(Aminomethyl)phenyl]propionic acid, FA130469, ST099097, SY276803, 4-AMINO-3-PHENYLBUTYRIC ACID [MI], CS-0028577, NS00018243, .BETA.-(AMINOMETHYL)HYDROCINNAMIC ACID, D10509, D96082, EN300-110013, .BETA.-(AMINOMETHYL)BENZENEPROPANOIC ACID, .BETA.-PHENYL-.GAMMA.-AMINOBUTYRIC ACID, Q419559, BRD-A66920069-001-01-3, Z1255487817
Theoretical properties:
molecular_formula: C10H13NO2
molecular_weight: 179.22 g/mol
exact_mass: 179.094628657 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 2
hydrogen_bond_acceptor_count: 3
rotatable_bond_count: 4
heavy_atom_count: 13
topological_polar_surface_area: 63.3 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
Descriptions:
{"pubchem": "Phenibut is an organonitrogen compound and an organooxygen compound. It is functionally related to a gamma-amino acid.", "chebi": null, "chembl": "PHENIBUT is a small molecule listed in the ChEMBL database and has reached clinical trial phase -1.0.", "wikipedia": "Phenibut, sold under the brand name Anvifen among others, is a central nervous system (CNS) depressant with anxiolytic effects, and is used to treat anxiety, insomnia, and for a variety of other indications. It is usually taken orally (swallowed by mouth), but may be given intravenously.\nSide effects of phenibut can include sedation, sleepiness, nausea, irritability, agitation, dizziness, euphoria, and sometimes headache, among others. Overdose of phenibut can produce marked central nervous system depression including unconsciousness. The medication is structurally related to the neurotransmitter \u03b3-aminobutyric acid (GABA), and hence is a GABA analogue. Phenibut is thought to act as a GABAB receptor agonist, similarly to baclofen and \u03b3-hydroxybutyrate (GHB). However, at low concentrations, phenibut mildly increases the concentration of dopamine in the brain, providing stimulatory effects in addition to the anxiolysis.\nPhenibut was developed in the Soviet Union and was introduced for medical use in the 1960s. Today, it is marketed for medical use in Russia, Ukraine, Belarus, Kazakhstan, and Latvia. The medication is not approved for clinical use in the United States and most of Europe, but it is sold on the Internet as a supplement and purported nootropic. Phenibut has been used recreationally and can produce euphoria as well as addiction, dependence, and withdrawal. It is a controlled substance in Australia, and it has been suggested that its legal status should be reconsidered in Europe as well. In Germany, phenibut is not approved as a drug and, as a food supplement, is controlled under the German New Psychoactive Substances Act.\nIn a 2023 assessment, the U.S. Food and Drug Administration (FDA) determined that phenibut does not meet the definition of a dietary ingredient, thereby making phenibut supplement products misbranded and illegal for marketing. FDA warning letters had been issued to supplement manufacturers marketing phenibut products as adulterated."}